ArticleCureus2025
The Significance of Newly Derived Disease Activity Parameters Neutrophil/Albumin Ratio, Neutrophil/Complement C3 Ratio, and Albumin/Globulin Ratio in a Group of Patients With Lupus Nephritis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLupus nephritis (LN) is the most serious manifestation of systemic lupus erythematosus (SLE), which worsens the course and prognosis of this autoimmune disease. The standard assays we use to assess LN activity still do not have sufficient sensitivity. The aim of this study was to determine the parameters neutrophil/albumin ratio (NAR), neutrophil/complement C3 ratio (NC3r), and albumin/globulin ratio (AGR) in patients with LN, as well as the significance of these parameters in comparison with the standard parameters that we use to determine the activity of lupus nephritis.
methodsOf the total number of subjects (72 patients) with lupus nephritis (mean age: 43.62 ± 14.38 years), who were included in this study, 50% (36) of the patients had active disease (group A-LN), and the other half had disease in remission (group R-LN). In addition to standard laboratory parameters, we also determined the derived parameters NAR, NC3r, and AGR.
resultsIn the group comparison, a significant difference was observed in the following parameters: albumin, complement C3, antinuclear antibody (ANA), anti-double-stranded DNA antibody (anti-ds-DNA Ab), proteinuria g/24h (proteins from 24 hours collected urine), and Systemic Lupus Erythematosus Activity Index/renal (SLEDAI/r) (p < 0.000). Correlation of NAR with total proteins (r = -0.359, p = 0.003), albumin (r = -0.590, p < 0.001), SLEDAI/r (r = 0.460, p < 0.001), and proteinuria g/24h (r = 0.515, p < 0.001) was significant in the A-LN group. Correlation of NC3r with total proteins (r = -0.340, p = 0.003), albumin (r = -0.584, p < 0.001), C3 (r = -0.474, p < 0.001), anti-ds-DNA Ab (r = 0.283, p = 0.019), proteinuria g/24h (r = 0.586, p < 0.001), and SLEDAI/r (r = 0.559, p < 0.001) was significant in the A-LN group. AGR in the A-LN group significantly correlated with albumin (r = 0.581, p < 0.001), C3 (r = 0.376, p = 0.023), and SLEDAI/r score (r = -0.354, p = 0.036). According to the coordinates on the receiver operating characteristic (ROC) curve for NAR, the cutoff value is 0.104, the sensitivity is 72.2%, and the specificity is 66.7%; for parameter NC3r, the cutoff value is 4.849, the sensitivity is 83.3%, and the specificity is 69.4%; and for AGR, the cutoff value is -1.608, the sensitivity is 30.6%, and the specificity is 63.9%.
conclusionOur data show a significant relationship between NAR, NC3r, and AGR and lupus activity. NC3r has proven to be the most significant in providing valuable data for identifying patients with active LN and as a simple indicator in clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.